FTAI Aviation Ltd vs Viatris Inc — how do they compare? FTAI Aviation Ltd trades at $169.74 (market cap $17.57B), while Viatris Inc trades at $17.62 (market cap $20.03B). The key difference: FTAI Aviation Ltd and Viatris Inc are close in size by market cap, and Viatris Inc pays the higher dividend (2.75%). Which is the better fit depends on your goals — on Pluang, investors hold FTAI Aviation Ltd for 22 Days and Viatris Inc for 57 Days on average.
| FTAI | VTRS | |
|---|---|---|
Market Cap | $17.57B | $20.03B |
Volume | 1,905,014 | 14,109,977 |
Sector | Industrials | Health |
52-Week High | $310.04 | $18.27 |
52-Week Low | $152.80 | $9.74 |
Typical Hold Time | 22 Days | 57 Days |
Enterprise Value | $20.69B | $32.15B |
Dividend Yield | 1.17% | 2.75% |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation Ltd. (FTAI) trades at $169.13, down 3.26% over 24 hours, with a bearish technical signal from moving averages. Recent financials show strong revenue growth to $2.51B in 2025 and a net income margin of 15.94%, but earnings have missed expectations for three consecutive quarters. The company announced a $500 million share repurchase program and a strategic aircraft acquisition, signaling management confidence. Valuation ratios are elevated, with a P/E of 37.35 and P/B of 43.49, reflecting high growth expectations.
The outlook for FTAI is mixed; analyst consensus is unanimously bullish with a $321.25 price target, but near-term risks include earnings misses and negative operating cash flow. Long-term growth drivers include expansion in aerospace products and power segments, though execution risks and market volatility could pressure the stock. Investors should weigh strong institutional support against fundamental headwinds.
Viatris (VTRS) trades at $17.625, up 0.77% with a bullish technical signal. The company shows mixed fundamentals with declining revenue from $16.3B in 2022 to $14.3B in 2025 and negative net income margins, though recent quarters have beaten EPS estimates. Positive cash flow trends and a $0.12 dividend signal financial stability. Analyst consensus is mixed with 38% buy ratings and a $22.17 price target suggesting 26% upside.
The outlook balances operational strength against profitability challenges. Investment appeal lies in value metrics (P/S 1.38), consistent earnings beats, and dividend yield, but risks include sustained negative margins, high debt, and competitive pressures. The stock's re-rating depends on margin improvement and pipeline execution.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →